Drug
Parsaclisib clinical trials
Also written INCB050465 and IBI376.
- studies test it
- 31
- open now
- 2
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the parsaclisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
31 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 15
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 5
Incyte Corporation (23) · Incyte Biosciences Japan GK (2) · Walter Hanel (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Fudan University (1) · Chinese PLA General Hospital (1) · Henan Cancer Hospital (1) · UNC Lineberger Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Itacitinib (2) · Ruxolitinib (2) · Lenalidomide (1) · R-CHOP Regimen (1) · Ibrutinib (1) · Bendamustine (1) · Obinutuzumab (1) · Romidepsin (1)
Studies
Open first, then newest update. How each study uses parsaclisib is read from its arms, and is right about nine times in ten.
Testing it · 31
- IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingPhase 2Chinese PLA General HospitalNCT05073250Written as IBI376
- Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingPhase 1/2Fudan UniversityNCT05238064Written as Parsaclisib
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingPhase 1/2Incyte Biosciences Japan GKNCT04661007Written as parsaclisib
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingPhase 2Incyte CorporationNCT04509700Written as Parsaclisib
- A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedPhase 1/2Incyte CorporationNCT04809467Written as parsaclisib
- PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedPhase 1Henan Cancer HospitalNCT05083208Written as Parsaclisib
- Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaTerminatedPhase 3Incyte CorporationNCT05073458Written as parsaclisinib
- To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedPhase 3Incyte CorporationNCT04551066Written as parsaclisib
- To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedPhase 3Incyte CorporationNCT04551053Written as parsaclisib
- A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)CompletedPhase 2Incyte CorporationNCT02998476Written as Parsaclisib
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedPhase 1Incyte CorporationNCT03039114Written as Parsaclisib
- A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)CompletedPhase 2Incyte CorporationNCT03144674Written as Parsaclisib
- A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaCompletedPhase 2Incyte CorporationNCT03538041Written as Parsaclisib
- A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorCompletedPhase 2Incyte CorporationNCT03235544Written as Parsaclisib
- A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaCompletedPhase 2Incyte CorporationNCT03126019Written as Parsaclisib
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedPhase 1Walter HanelNCT04774068Written as Parsaclisib
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedPhase 2Incyte Biosciences Japan GKNCT04434937Written as parsaclisib
- IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT04298879Written as IBI376
- A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedPhase 2Incyte CorporationNCT02718300Written as Parsaclisib
- A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedPhase 1Incyte CorporationNCT03314922Written as Parsaclisib
See all 31 studies that test parsaclisib →
Given in every arm · 5 — parsaclisib is usual care beside what is tested
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaActive, not recruitingPhase 1Mayo ClinicNCT04323956Written as Parsaclisib
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedPhase 1Incyte CorporationNCT03424122Written as Parsaclisib
- Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05867030Written as parsaclisib
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedPhase 1/2Incyte CorporationNCT02018861Written as Parsaclisib
- An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02265510Written as INCB050465
Codes
What other systems call parsaclisib · ClinicalTrials.gg INT001234
- MeSH (NLM) C000656179parsaclisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) OS7097575KPARSACLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76802661parsaclisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113434ParsaclisibOne source FDA
- DrugBank DB14867One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656179 | parsaclisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OS7097575K | PARSACLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76802661 | parsaclisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113434 | Parsaclisib | One source FDA |
| DrugBank | DB14867 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.